Lonza and Vineti announced their partnership in the cell and gene therapy field and across Lonza’s ‘vein-to-vein’ delivery network. As a part of this commitment, both Lonza and Vineti become preferred partners, respectively for patient tissue tracking and for contract development and manufacturing services in cell and gene therapy.
The unique partnership comprises a fully integrated offering including logistics, scheduling, distribution, Chain of Condition, Chain of Custody, Chain of Identity, and Lonza’s proprietary solutions such as MODA-ES™.With the goal of seamless servicefor Lonza’s customers and their patients, Lonza and its partners will work to remove the supply chain hurdles faced by developers of personalized therapeutics -including autologous therapies, matched-allogeneic therapies, and personalized cancer vaccines -as they prepare for the commercial launch of their therapies.
The Vineti supply chain orchestration (SCO) platform, the only independent solution known today to serve commercial cell & gene therapy products,will help Lonza’s customers to keep a real-time end-to-end connection between Lonza and the points of care that prescribe their therapies. Together, the Lonza-Vineti solution will seek to provide bio pharmaceutical developers with a pre-integrated SCO and manufacturing system that will offer digital, optimized end-to-end traceability and control. The partnership aimsto establish faster, simpler operations and scale for cell and gene therapies, and to reduce the time that biopharmaceutical developers need to spend evaluating, implementing, and validating different systems. The partnership will also be working to provide this integrated system worldwide, using Lonza’s global manufacturing presence and Vineti’s ever-expanding network of leading medical centers.
The Lonza-Vineti integrated solution will include Lonza’s proprietary solutions such asMODA-ES™, a next-generation electronic batch record execution solution that offers specific functionalities for cell and gene therapies manufacturing.
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers’ preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment andto the preservation and protection of the world where we live.Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com
Vineti is the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges that patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of individualized therapies. Now a fully independent company, Vineti offers a digital platform of record to integrate logistics, manufacturing and clinical data for personalized therapies. The Vineti platform supports the full continuum of patient-specific therapies, including cancer vaccines and autologous and allogeneic therapies. The company is expanding rapidly, and the Vineti platform will be in use in hundreds of leading medical centers worldwide in 2019, on behalf of multiple biopharmaceutical partners